SynthesisNature reviews. Nephrology2014
Cardiovascular disease in CKD in 2013: Reducing cardiovascular risk--light at the end of the tunnel.
Synthesis in Nature reviews. Nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Performance evaluation between two automated biochemical analyzer systems: Roche Cobas 8000 and Mindray BS2000M.Journal of medical biochemistry · 2022Article
- Emergency Department/Urgent Care as Usual Source of Care and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort Study.Kidney medicine · 2022Article
- Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Article
- Estimated Glomerular Filtration Rate, Activation of Cardiac Biomarkers and Long-Term Cardiovascular Outcomes: A Population-Based Cohort.Mayo Clinic proceedings · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During 2013, a meta-analysis provided evidence that cystatin C improves estimated glomerular filtration rate in cardiovascular risk categorization in chronic kidney disease (CKD). Another study showed that low diastolic blood pressure (DBP) is harmful in patients with CKD, challenging the paradigm of treating elevated systolic blood pressure regardless of DBP. Overall, mortality rates in CKD have decreased but further improvement is required.
Indexed as
Identifiers
24322975What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.